Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.

Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.

Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.

MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.

Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.

PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.

Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.

Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.